Press Releases for DNA

Press Releases
Genentech Announces Voluntary Withdrawal of Raptiva from the U.S. Market
FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)
Roche Completes Acquisition of Genentech
Roche Completes Tender Offer for Genentech
Zacks Analyst Blog Highlights: Vivo Participacoes, America Movil, TIM Participacoes, Amylin Pharmaceuticals, Inc. And Eli Lilly.
Capacity Crowd at 2009 Southeast Venture Conference Optimistic About Market - Mar 19 2009 6:53PM
Capacity Crowd at 2009 Southeast Venture Conference Optimistic About Market - Mar 19 2009 2:52PM
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Zacks Industry Outlook Highlights: Roche, Genentech, Gilead Sciences and CV Therapeutics
Over 80 Life Science Industry Exhibitors at the NYBA Annual Meeting
Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
Media Invite - The Pacific Northwest's Largest Life Sciences Investment Conference, March 17-18, 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Genentech Urges Shareholders to Take No Action With Respect to Revised Offer From Roche
Roche Increases Offer Price for Genentech Shares to US$ 93.00 per Share and Extends Offer
Tower C. Snow, Jr. Joins Howard Rice
PDL BioPharma Announces Fourth Quarter and Full Year 2008 Financial Results
MattsonJack to Present at Cancer Progress Conference: Pricing Issues in a Strained Economy
Genentech Receives Final Notification Upholding Cabilly Patent in Reexamination Proceeding
Genentech Announces March 2, 2009 Webcast of Investment Community Meeting
Genentech Special Committee Rejects Roche’s $86.50 Offer as Inadequate
MattsonJack Forecasting Workshop Addresses Critical Issues in Pharmaceutical Forecasting
Kauffman Research Roundup Points to Critical Role Entrepreneurs Play in the Economy
Research and Markets: Pipeline Insight: Cancer Overview: 6 Tumor Types Covered in This Report Are Forecast to Account for 961,000 New Cases of Cancer and $4,789m in Sales By 2017
Genentech Urges Shareholders to Take No Action With Respect to Unsolicited Tender Offer From Roche
Research and Markets: 373 Identified Molecular Targeted Cancer Candidates Have a Forecast Sales Potential Of Up To $7.31 Billion in the Seven Major Pharmaceutical Markets By 2017 - Feb 4 2009 11:51PM
Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer
MattsonJack to Present at Impact of Medicare Reform in 2009 - 5th Annual Oncology Economics Summit
Special Committee of Genentech Board of Directors Responds to Roche’s Announced Intention to Commence a Tender Offer
Stock Preacher Issues Technical Trade Alerts on: SKS, DNA, LCC, CHTR, FNSR, AZO
ARCA Biopharma, Inc. Announces Commencement of Trading on the NASDAQ Global Market Under the Symbol "ABIO"
Stock Preacher Issues Technical Trade Alerts on: SKS, LCC, YHOO, DNA, BAC
U.S. Stroke Management Products Market Will Grow From $4.8 Billion to $6.4 Billion By 2012, As Forecast By a New Medtech Insight/ Elsevier Business Intelligence Market Analysis Report
Genentech Announces Full Year and Fourth Quarter 2008 Results
BridgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on DNA, GLW, GD and LMT
Genentech Announces January 15 Webcast of Financial and Other Business Results
Phase III Study Showed Rituxan® Decreased the Progression of Joint Damage in Patients with Early Rheumatoid Arthritis (RA)
Zacks Analyst Blog Highlights: Genentech Inc., Hess Corporation, DPL Inc., Lamar Advertising Co., And Cadence Design Systems, Inc. - Dec 16 2008 11:52PM
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival in Advanced Breast Cancer
MattsonJack Study Reveals Cachexia Emerging As a Lucrative Opportunity for Pharma Companies
Genentech Issues Dear Healthcare Provider Letter Regarding a 2nd Case of PML in a Raptiva Patient
Best Practice Database Shares Best Practices in Biopharma Public Relations
Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
Rituxan Data in Patients with Rheumatoid Arthritis to Be Presented at the American College of Rheumatology Annual Scientific Meeting
Reminder - Register Your Company Now for the 2009 IR Global Rankings
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Zacks Analyst Blog Highlights: Genentech, Inc., KeyCorp, Fifth Third Bancorp., Comerica Inc. And Altera Corp.
Seven Summits Research Releases Alerts on CHK, V, DNA, UPS, and TOL
Genentech Announces Third Quarter 2008 Results
CancerNFluence(R) Database Considered a "Must Have" for Clients Focused on Enhancing Marketing, Sales, and R&Amp;D Effectiveness
Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed Chronic Lymphocytic Leukemia
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy
Genentech Issues Dear Healthcare Provider Letter Regarding a Reported Case of PML in a Raptiva Patient
Genentech Announces October 14 Webcast of Financial and Other Business Results
Seven Summits Research Releases Alerts on INTC, AXP, DNA, DD, and SBUX
Investors Score Gains As High As 20% in Just Days With "Stock Alerts"
Genentech Announces Vice President Appointment in Research
Zacks Analyst Interview Highlights: Genentech, ImClone Systems, Bristol-Myers Squibb and Celgene
BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
Stock Alert Service Starts New 100% Perfection Streak
Genentech Special Committee of Independent Directors Responds to Roche Proposal
Zacks Bull and Bear of the Day Highlights: Genentech, Comerica, Consolidated Edison, Aetna and Dr. Pepper Snapple
Genentech Forms Special Committee of Independent Directors to Review Roche Proposal
Cohen, Milstein, Hausfeld & Toll, P.L.L.C. Files Lawsuit Concerning Genentech Buyout
100% Perfect Stock Picking Streak Ends After 106th Trade
UPI NewsTrack Business - Jul 21 2008 5:54PM
UPI NewsTrack Business - Jul 21 2008 12:54PM
Genentech Announces Receipt of Proposal From Roche
Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash
Genentech Announces Second Quarter 2008 Results
Seven Summits Research Releases Comments on GOOG, DNA, EBAY, NUE and RS
Zacks Analyst Blog Highlights: Sangamo Biosciences, Dow AgroSciences, Sigma-Aldrich, Genentech and Progressive Corp. - Business Wire
Seven Summits Research Releases Comments on DNA, PCLN, TWX, SBUX, and ENER
Genentech Announces July 14 Webcast of Financial and Other Business Results
Genentech Settles Dispute Related to Cabilly Patent
BellwetherReport.com Analyst Report on HRS, BMY, JBL and DNA
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Women with Advanced HER2-Negative Breast Cancer
Streak of 100% Profitable Trades Is Undeterred by a Market in Recession
Genentech Announces June 2 Webcast Discussion of Data Presented at ASCO - May 27 2008 12:57AM
Seven Summits Research Releases Comments on SLB, DNA, WFC, FNM, and LOW - May 27 2008 1:24AM
Genentech Provides Update on Avastin Program
Genentech Provides Update on Studies of Investigational Biooncology Agents to Be Presented at the American Society of Clinical Oncology Meeting - May 27 2008 12:55AM
Leading Stock Newsletter Off to a Fast Start in May, Up 15% - May 27 2008 1:17AM
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Salient Investment Newsletter Rebounds From Arduous Month, Up 11% in April - May 27 2008 1:16AM
Seven Summits Research Releases Alerts on COP, MA, DNA, IR, and MVSN - May 27 2008 1:16AM
Genentech Announces Decision in Contract Dispute
Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
Genentech Extends Stock Repurchase Program
Genentech and Biogen Idec Announce Top-Line Results from a Phase II/III Clinical Trial of Rituxan in Primary-Progressive Multiple Sclerosis
Genentech Announces First Quarter 2008 Results
Seven Summits Research Releases Comments on MSFT, DNA, VZ, HON and BBBY
Foremost Investment Newsletter Portfolio Has First Down Month Since May of 2007
SmallCap Sentinel: The Ever-Increasing Applications for Non-Controversial Adult Stem Cells
Protein Design Labs Sublicenses Rights to Develop Antibody-Drug Conjugates for Prostate Cancer to Genentech, Inc.